Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically? (Q35203844)

7 August 2017

1 reference

title

Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically? (English)

1 reference

7 August 2017

main subject

acute myeloid leukemia

1 reference

1

Guido Marcucci

1 reference

7 August 2017

3

Clara D Bloomfield

1 reference

7 August 2017

2

Michael A Caligiuri

1 reference

7 August 2017

publication date

1 September 2003

1 reference

European Journal of Haematology

7 August 2017

published in

1 reference

7 August 2017

volume

71

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

143-154

1 reference

7 August 2017

cites work

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Clinical applicability of the evaluation of minimal residual disease in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

Persistence of RARa‐PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long‐term remission of acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Expression of AML1/MTG8 transcripts in clonogenic cells grown from bone marrow of patients in remission of acute myeloid leukaemia with t(8;21)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Real time quantitative PCR

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

A novel method for real time quantitative RT-PCR.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Integration of molecular methods for detection of balanced translocations in the diagnosis and follow-up of patients with leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00131.X

7 January 2021

10.1034/J.1600-0609.2003.00131.X

Identifiers

DOI

1 reference

7 August 2017

1 reference